KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) EBT Margin (2016 - 2026)

Eli Lilly filings provide 18 years of EBT Margin readings, the most recent being 44.7% for Q1 2026.

  • On a quarterly basis, EBT Margin rose 1755.0% to 44.7% in Q1 2026 year-over-year; TTM through Mar 2026 was 43.08%, a 1533.0% increase, with the full-year FY2025 number at 39.48%, up 1133.0% from a year prior.
  • EBT Margin hit 44.7% in Q1 2026 for Eli Lilly, up from 42.85% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 44.7% in Q1 2026 to a low of 4.5% in Q3 2023.
  • Median EBT Margin over the past 5 years was 27.15% (2025), compared with a mean of 28.43%.
  • Biggest five-year swings in EBT Margin: plummeted -1805bps in 2023 and later skyrocketed 2721bps in 2025.
  • Eli Lilly's EBT Margin stood at 28.71% in 2022, then dropped by -7bps to 26.82% in 2023, then surged by 39bps to 37.23% in 2024, then grew by 15bps to 42.85% in 2025, then increased by 4bps to 44.7% in 2026.
  • The last three reported values for EBT Margin were 44.7% (Q1 2026), 42.85% (Q4 2025), and 41.09% (Q3 2025) per Business Quant data.